What Are Peptides? Types, Benefits, Uses in Medicine

What Exactly Is a Peptide?

Peptides are molecules built from amino acids joined end-to-end by covalent peptide bonds. The body produces thousands of them naturally. They carry instructions between cells, regulate hormones, control inflammation, and direct tissue repair.

The size boundary between a peptide and a protein is somewhat arbitrary, but the working clinical definition sets the cutoff at roughly 50 amino acids. Below that threshold: peptide. Above it: protein or large-molecule biologic. This size distinction matters for manufacturing, stability, and regulatory classification.

Peptide Bonds: The Chemical Foundation

Each peptide bond forms when the carboxyl group of one amino acid reacts with the amino group of the next, releasing water. That bond is planar and relatively rigid, which gives each peptide a defined three-dimensional shape. That shape determines which receptor the peptide binds and, therefore, what it does in the body [1].

Endogenous vs. Synthetic Peptides

The human body synthesizes peptides continuously through ribosomal translation and post-translational cleavage of larger precursor proteins. Insulin, for example, is cleaved from proinsulin in pancreatic beta cells. Synthetic or recombinant peptides mimic, modify, or replace these endogenous signals. Many therapeutic peptides carry chemical modifications, such as fatty acid side chains on semaglutide, that extend half-life far beyond the native molecule [2].

How Peptides Differ from Small-Molecule Drugs

Small molecules (aspirin, metformin, statins) are synthesized chemically and typically weigh under 500 Daltons. Most peptides range from 500 to 5,000 Daltons. They are more selective for their targets but are also more fragile: proteases in the gut degrade most peptides before absorption, which is why injection remains the dominant delivery route. Oral peptide delivery requires co-formulation strategies, such as the sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) absorption enhancer used in oral semaglutide [3].

Major Classes of Therapeutic Peptides

More than 80 peptide drugs have received FDA approval, spanning at least a dozen therapeutic categories [4]. The classification below organizes them by mechanism and clinical use.

GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid incretin hormone secreted by intestinal L-cells after meals. It stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic GLP-1 receptors.

Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are the most studied members of this class. In the STEP-1 trial (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [5]. The SELECT cardiovascular outcomes trial (N=17,604) showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity who had established cardiovascular disease but no diabetes [6].

Tirzepatide (Mounjaro, Zepbound) adds GIP receptor agonism to GLP-1 agonism. In SURMOUNT-1 (N=2,539), the 15 mg dose produced 20.9% mean weight loss at 72 weeks [7].

Growth Hormone Secretagogues

These peptides stimulate the pituitary to release growth hormone (GH) rather than replacing GH directly. The two main sub-types are:

GHRH analogs. Sermorelin and tesamorelin are synthetic analogs of growth hormone-releasing hormone. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy; a 26-week trial (N=412) showed a 15.2% reduction in visceral adipose tissue versus placebo (P<0.0001) [8].

Ghrelin mimetics (GHRPs). Ipamorelin, hexarelin, and GHRP-2 bind the ghrelin receptor (GHS-R1a) to trigger pulsatile GH release. Ipamorelin is selective for GH release with minimal cortisol or prolactin stimulation, making it a popular compound in sports-medicine and longevity clinics, though it lacks FDA approval for most of these off-label indications [9].

Insulin and Insulin Analogs

Insulin is the oldest approved peptide drug, first used clinically in 1922. Modern analogs such as insulin lispro, glargine, and degludec are engineered for predictable pharmacokinetics. Degludec (Tresiba) has a half-life exceeding 25 hours, enabling once-daily dosing with lower hypoglycemia risk compared to NPH insulin in randomized trials [10].

Peptide Hormones for Bone and Calcium

Teriparatide (Forteo) is a 34-amino-acid fragment of parathyroid hormone (PTH 1-34). The key fracture prevention trial (N=1,637 postmenopausal women) showed it reduced new vertebral fractures by 65% relative to placebo over 21 months [11]. Abaloparatide (Tymlos), a PTH-related protein analog, showed similar efficacy in the ACTIVE trial (N=2,463) [12].

Calcitonin, a 32-amino-acid peptide from thyroid C-cells, was used for osteoporosis and hypercalcemia for decades, though teriparatide has largely replaced it for fracture prevention given superior evidence.

Antimicrobial Peptides

The innate immune system produces hundreds of cationic antimicrobial peptides (AMPs), including defensins and cathelicidins, that disrupt bacterial membranes. Synthetic AMPs are in clinical development as alternatives to conventional antibiotics for drug-resistant organisms. Omiganan, a synthetic indolicidin analog, completed Phase III trials for catheter-site infections, though it did not reach approval for that indication [13].

Peptides in Oncology

Peptide receptor radionuclide therapy (PRRT) uses somatostatin analogs, particularly lutetium-177 DOTATATE (Lutathera), to target neuroendocrine tumors. In the NETTER-1 trial (N=229), lutetium-177 DOTATATE improved progression-free survival significantly versus high-dose octreotide LAR (median PFS not reached vs. 8.4 months) [14]. The FDA approved Lutathera in January 2018.

How Peptides Work in the Body

Peptides exert their effects primarily through receptor binding, though some penetrate cells or directly modulate enzyme activity.

Receptor-Mediated Signaling

Most peptide hormones bind G-protein-coupled receptors (GPCRs) on cell surfaces. GLP-1 receptors, GH-releasing hormone receptors, and somatostatin receptors are all GPCRs. Binding activates intracellular second-messenger cascades (cAMP, PKA, MAPK) that alter gene expression, enzyme activity, and ion channel conductance within seconds to minutes [15].

Half-Life and Modification Strategies

Native endogenous peptides are cleared rapidly. GLP-1 itself has a plasma half-life of roughly 2 minutes because dipeptidyl peptidase-4 (DPP-4) cleaves it at position 2. Pharmaceutical engineers extend half-life through:

• Fatty acid conjugation: Semaglutide carries a C18 fatty diacid chain that promotes albumin binding, extending half-life to approximately 165 hours [2].
• PEGylation: Polyethylene glycol chains shield peptides from proteolysis.
• Amino acid substitution: Replacing L-amino acids with D-amino acids or alpha-methylated residues resists protease cleavage.

Bioavailability Challenges

Oral bioavailability of unmodified peptides is below 1% in most cases. The SNAC-based oral semaglutide formulation (Rybelsus 14 mg) achieves roughly 1% absolute bioavailability, which is sufficient for therapeutic effect because of the molecule's high potency [3]. Injectable formulations circumvent the GI barrier entirely and remain the standard for most peptide drugs.

Evidence-Based Benefits of Peptide Therapy

The table below organizes approved peptide drug classes by their primary evidence base, showing trial name, population, primary endpoint, and magnitude of benefit. This framework was developed by the HealthRX medical team to help clinicians quickly locate the strongest data for each class.

| Drug Class | Index Trial | N | Primary Outcome | Magnitude | |---|---|---|---|---| | GLP-1 RA (semaglutide 2.4 mg) | STEP-1 | 1,961 | % body weight change at 68 wks | 14.9% loss vs. 2.4% placebo | | Dual GIP/GLP-1 RA (tirzepatide 15 mg) | SURMOUNT-1 | 2,539 | % body weight change at 72 wks | 20.9% loss vs. 3.1% placebo | | PTH analog (teriparatide) | Neer et al. 2001 | 1,637 | New vertebral fracture rate | 65% RRR vs. Placebo | | PRRT (lutetium-177 DOTATATE) | NETTER-1 | 229 | Progression-free survival | Median PFS not reached vs. 8.4 mo | | GHRH analog (tesamorelin) | Falutz et al. 2010 | 412 | Visceral fat change at 26 wks | 15.2% reduction vs. Placebo |

Weight Management and Metabolic Health

GLP-1 receptor agonists have shifted the treatment of obesity from lifestyle counseling and bariatric surgery toward pharmacotherapy. The 2023 American Gastroenterological Association guideline states: "Clinicians should offer pharmacological therapy in conjunction with intensive behavioral therapy for patients with obesity" [16]. The SELECT trial demonstrated that cardiovascular protection from semaglutide extends beyond glucose control, since all participants in that trial had no diabetes at enrollment [6].

Bone Health

The Endocrine Society's 2019 clinical practice guideline on osteoporosis pharmacotherapy recommends teriparatide and abaloparatide as first-line anabolic therapy for patients at very high fracture risk, defined as prior vertebral or hip fracture, T-score at or below -3.0, or fracture while on antiresorptive therapy [17].

Neuroendocrine Tumor Management

The FDA label for Lutathera specifies use in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Four cycles of 7.4 GBq (200 mCi) every 8 weeks is the approved dosing schedule. The NETTER-1 objective response rate was 18% for Lutathera versus 3% for comparator [14].

Peptides Being Studied but Not Yet Approved

Several peptides in widespread clinical or research use lack FDA approval for the indications most discussed in wellness and anti-aging contexts. Prescribers and patients should understand this distinction.

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a gastric protein. Rodent studies show accelerated tendon healing, gut mucosal repair, and neuroprotection, but no completed Phase II or Phase III human trials have been published as of early 2025 [18]. The FDA has not approved BPC-157 for any indication, and it is not permitted in compounded formulations under current FDA guidance for 503A and 503B compounders.

Thymosin Beta-4 (TB-500)

Thymosin beta-4 is a 43-amino-acid actin-sequestering peptide with roles in wound healing and angiogenesis. A 2010 pilot study (N=17) suggested improved cardiac function post-myocardial infarction, but larger controlled data are absent [19]. Like BPC-157, it is not FDA-approved and sits in a regulatory gray zone for compounding.

Ipamorelin / CJC-1295

Ipamorelin (a GHRP) and CJC-1295 (a modified GHRH analog) are often combined to produce sustained GH pulses. Small studies in healthy adults document GH-axis stimulation, but published data on clinical endpoints such as body composition, cognition, or longevity are limited to short-duration, small-sample investigations [9]. The FDA has not approved either peptide for any indication, and in 2023 the agency removed several GHRPs from the 503A bulk drug substance list, restricting their legal compounding.

Risks, Side Effects, and Safety Considerations

No pharmacological agent is free of risk. Peptide drugs are no exception.

GLP-1 Receptor Agonists

Common adverse effects include nausea (reported in 44% of semaglutide 2.4 mg patients in STEP-1 versus 16% placebo), vomiting, diarrhea, and constipation [5]. The FDA label carries warnings for thyroid C-cell tumors (based on rodent carcinogenicity studies), pancreatitis, and gallbladder disease. Patients with personal or family history of medullary thyroid carcinoma or MEN2 should not use GLP-1 receptor agonists.

Muscle mass loss alongside fat loss is a clinical concern. A secondary analysis of STEP-1 data showed that roughly 39% of weight lost was lean mass, a figure that motivates co-prescribing of resistance training and adequate protein intake [20].

Growth Hormone Secretagogues

Excess GH stimulation raises insulin-like growth factor-1 (IGF-1). Chronically elevated IGF-1 is associated with increased risk of colon and prostate cancer in epidemiological studies, though causality from short-term therapeutic use is unproven [21]. Water retention, carpal tunnel symptoms, and joint pain are common dose-dependent side effects.

Antimicrobial and Research Peptides

Unapproved peptides sourced from compounding pharmacies or research chemical suppliers carry risks from impurity profiles, inaccurate dosing, and absence of pharmacovigilance data. The FDA's 2023 guidance document on compounded drug products explicitly advises clinicians to verify that any compounded peptide appears on the current 503A or 503B bulk drug substance list before prescribing [22].

How Peptides Are Administered

Route of administration shapes both pharmacokinetics and patient experience.

Subcutaneous Injection

Most peptide drugs are administered subcutaneously using fine-gauge auto-injectors or insulin syringes. Semaglutide 2.4 mg (Wegovy) uses a pre-filled pen injected once weekly into the abdomen, thigh, or upper arm. Tesamorelin is injected daily into the abdomen. Teriparatide was injected daily for up to 24 months; its successor, abaloparatide, follows the same schedule.

Oral Formulations

Oral semaglutide (Rybelsus) is approved for type 2 diabetes at 7 mg or 14 mg daily. It must be taken on an empty stomach with no more than 4 oz of water and no food or medication for 30 minutes after dosing. These requirements reflect the narrow absorption window created by the SNAC absorption enhancer [3].

Inhalation and Nasal Routes

Calcitonin-salmon nasal spray (Miacalcin) was used for postmenopausal osteoporosis for many years, though the European Medicines Agency withdrew most nasal calcitonin products in 2012 after a review found a small increased cancer signal in long-term users [23].

Intravenous and Intramuscular Routes

Lutetium-177 DOTATATE is administered as a slow intravenous infusion over 30 minutes. Amino acid co-infusion is given simultaneously to reduce renal uptake of radioactivity, a nephroprotection protocol specified in the prescribing information [14].

The Regulatory Field for Peptides

Regulatory classification determines whether a peptide is a drug, a biologic, a dietary supplement, or something else entirely.

FDA Drug Approval

Most approved peptide drugs went through the standard new drug application (NDA) or biologics license application (BLA) pathway. The FDA's 2023 draft guidance on the development of peptide drug products acknowledges that peptides occupy a middle ground between small molecules and biologics [4].

Compounding Regulations

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacists to compound drugs for individual patients based on a valid prescription. Section 503B covers outsourcing facilities. Both sections restrict which active pharmaceutical ingredients may be used. The FDA publishes and updates a bulk drug substance list for each section. Several peptides popular in wellness contexts, including BPC-157 and certain GHRPs, are not on these lists and therefore cannot be legally compounded [22].

Dietary Supplements

The Dietary Supplement Health and Education Act (DSHEA) of 1994 does not allow peptide drugs marketed with disease claims to be sold as supplements. Some companies sell collagen peptides and other food-derived peptides as supplements, which is permissible when no drug claim is made. The clinical evidence for oral collagen peptides on joint pain and skin elasticity is modest but growing, with a 2019 meta-analysis (N=805 across multiple trials) finding statistically significant improvements in skin hydration and elasticity [24].

Frequently Asked Questions